Literature DB >> 19221108

Expression and localisation of insulin receptor substrate 2 in normal intestine and colorectal tumours. Regulation by intestine-specific transcription factor CDX2.

S Modica1, A Morgano, L Salvatore, M Petruzzelli, M-T Vanier, R Valanzano, D L Esposito, G Palasciano, I Duluc, J-N Freund, R Mariani-Costantini, A Moschetta.   

Abstract

BACKGROUND AND AIMS: Self-renewal and differentiation of intestinal epithelium is a tightly regulated process, whose perturbations are implicated in human colorectal tumourigenesis. The insulin/insulin-like growth factor (IGF) signalling pathway may play an important role in intestinal epithelium homeostasis. Insulin receptor substrate 2 (IRS2) is a poorly characterised component in this pathway.
METHODS: Using complementary in vitro and in vivo human and murine models, expression (mRNA and protein levels), localisation (immunohistochemistry) and regulation of IRS2 were investigated in the normal intestine and colorectal tumours. In silico analysis of the human IRS2 promoter was performed together with reporter and chromatin immunoprecipitation assays.
RESULTS: Significant IRS2 expression was detected in the intestine, with specific protein localisation in the villus region of the ileum and in the surface epithelium of the colon. In human HT29 and Caco2 cells, IRS2 mRNA levels increased with spontaneous and induced differentiation, together with CDX2 (caudal-related homeobox protein 2), P21 and KLF4 (Krüppel-like factor 4). Adenoviral infection with human CDX2 induced IRS2 expression in APC- (adenomatous polyposis coli) and beta-catenin-mutated cells. On the other hand, IRS2 downregulation was observed in differentiated enterocytes after adenoviral infection with short hairpin CDX2 (shCDX2), in the intestine of CDX2 heterozygous mice and in colorectal tumours of Apc(Min/+) and patients with familial adenomatous polyposis (FAP). The human IRS2 promoter region presents several CDX2-binding sites where CDX2 immunoprecipitated in vivo. IRS2 reporters were functionally activated via CDX2 and blocked via a dominant-negative CDX2 protein.
CONCLUSIONS: Combining gain- and loss-of-function approaches, an intriguing scenario is presented whereby IRS2 is significantly expressed in the apical intestinal compartment and is directly controlled by CDX2 in normal intestine and tumours.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221108     DOI: 10.1136/gut.2008.158386

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Dual role of insulin-like growth factor-1 in acetyl-CoA carboxylase-alpha activity in human colon cancer cells HCT-8: downregulating its expression and phosphorylation.

Authors:  Di-Xian Luo; Xu-hong Peng; Yan Xiong; Duan-Fang Liao; Deliang Cao; Longjiang Li
Journal:  Mol Cell Biochem       Date:  2011-06-03       Impact factor: 3.396

2.  Insulin receptor isoform switching in intestinal stem cells, progenitors, differentiated lineages and tumors: evidence that IR-B limits proliferation.

Authors:  Sarah F Andres; James G Simmons; Amanda T Mah; M Agostina Santoro; Laurianne Van Landeghem; P Kay Lund
Journal:  J Cell Sci       Date:  2013-10-14       Impact factor: 5.285

Review 3.  Extending the functions of the homeotic transcription factor Cdx2 in the digestive system through nontranscriptional activities.

Authors:  Jean-Noël Freund; Isabelle Duluc; Jean-Marie Reimund; Isabelle Gross; Claire Domon-Dell
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

4.  CDX2 regulates multidrug resistance 1 gene expression in malignant intestinal epithelium.

Authors:  Yuji Takakura; Takao Hinoi; Naohide Oue; Tatsunari Sasada; Yasuo Kawaguchi; Masazumi Okajima; Aytekin Akyol; Eric R Fearon; Wataru Yasui; Hideki Ohdan
Journal:  Cancer Res       Date:  2010-08-10       Impact factor: 12.701

5.  The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer.

Authors:  Diana L Esposito; Federica Aru; Rossano Lattanzio; Annalisa Morgano; Michela Abbondanza; Reza Malekzadeh; Faraz Bishehsari; Rosa Valanzano; Antonio Russo; Mauro Piantelli; Antonio Moschetta; Lavinia Vittoria Lotti; Renato Mariani-Costantini
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

6.  CDX2 autoregulation in human intestinal metaplasia of the stomach: impact on the stability of the phenotype.

Authors:  Rita Barros; Luis Teixeira da Costa; João Pinto-de-Sousa; Isabelle Duluc; Jean-Noel Freund; Leonor David; Raquel Almeida
Journal:  Gut       Date:  2010-12-09       Impact factor: 23.059

7.  Cdx2 homeoprotein inhibits non-homologous end joining in colon cancer but not in leukemia cells.

Authors:  Benjamin Renouf; Christine Soret; Thoueiba Saandi; François Delalande; Elisabeth Martin; Marie Vanier; Isabelle Duluc; Isabelle Gross; Jean-Noël Freund; Claire Domon-Dell
Journal:  Nucleic Acids Res       Date:  2011-12-20       Impact factor: 16.971

8.  Distinct human stem cell populations in small and large intestine.

Authors:  Julie M Cramer; Timothy Thompson; Albert Geskin; William LaFramboise; Eric Lagasse
Journal:  PLoS One       Date:  2015-03-09       Impact factor: 3.240

9.  Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer.

Authors:  Diana Liberata Esposito; Fabio Verginelli; Sonia Toracchio; Sandra Mammarella; Laura De Lellis; Cinzia Vanni; Antonio Russo; Renato Mariani-Costantini; Alessandro Cama
Journal:  Oncol Rep       Date:  2013-07-18       Impact factor: 3.906

10.  Biologically anchored knowledge expansion approach uncovers KLF4 as a novel insulin signaling regulator.

Authors:  Annamalai Muthiah; Morgan S Angulo; Natalie N Walker; Susanna R Keller; Jae K Lee
Journal:  PLoS One       Date:  2018-09-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.